

Rachel E Sobel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4546623/rachel-e-sobel-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

447
citations

11
h-index

21
g-index

23
ext. papers

490
ext. citations

3.6
avg, IF

2.79
L-index

#	Paper	IF	Citations
23	A web-based survey of UK pharmacists to assess the effectiveness of Viagra Connect additional risk minimisation measures.. <i>International Journal of Clinical Pharmacy</i> , 2022 , 1	2.3	
22	The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1532-1539	2.6	2
21	Evaluation of the Effectiveness of Additional Risk Minimization Measures for Voriconazole in the EU: Findings and Lessons Learned from a Healthcare Professional Survey. <i>Pharmaceutical Medicine</i> , 2019 , 33, 121-133	2.3	6
20	A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool. <i>Drug Safety</i> , 2019 , 42, 1365-1376	5.1	
19	The Role of Pharmacoepidemiology in Industry 2019 , 98-125		1
18	Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 332-339	2.6	12
17	A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records. <i>Pharmaceutical Medicine</i> , 2018 , 32, 31-37	2.3	4
16	Real World Evidence: Time for a Switch?. <i>Drug Safety</i> , 2018 , 41, 1309-1312	5.1	2
15	Re: Letter written in reaction to "Pregabalin prescriptions in the United Kingdom: a drug utilisation study of The Health Improvement Network (THIN) primary care database", by Pottegård et al. - The authors (Asomaning et al.) respond. <i>International Journal of Clinical Practice</i> , 2016 , 70, 697-8	2.9	
14	Pregabalin prescriptions in the United Kingdom: a drug utilisation study of The Health Improvement Network (THIN) primary care database. <i>International Journal of Clinical Practice</i> , 2016 , 70, 380-8	2.9	27
13	Computer-assisted expert case definition in electronic health records. <i>International Journal of Medical Informatics</i> , 2016 , 86, 62-70	5.3	25
12	Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project. <i>Arthritis Care and Research</i> , 2015 , 67, 529-37	4.7	7
11	Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry. <i>Pediatric Rheumatology</i> , 2014 , 12, 29	3.5	21
10	Using registries to identify adverse events in rheumatic diseases. <i>Pediatrics</i> , 2013 , 132, e1384-94	7.4	21
9	Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry. <i>Arthritis Care and Research</i> , 2010 , 62, 800-4	4.7	20
8	Integrating evidence from multiple sources to evaluate post-approval safety: an example of sildenafil citrate and cardiovascular events. <i>Current Medical Research and Opinion</i> , 2008 , 24, 1861-8	2.5	8
7	Cardiovascular outcomes among sildenafil users: results of the International Men's Health Study. <i>International Journal of Clinical Practice</i> , 2008 , 62, 367-73	2.9	11

6	NAION and treatment of erectile dysfunction: reply from Pfizer. <i>British Journal of Ophthalmology</i> , 2006 , 90, 927	5.5	7
5	Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. <i>International Journal of Clinical Practice</i> , 2006 , 60, 500-3	2.9	50
4	Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. <i>American Journal of Cardiology</i> , 2001 , 87, 663-6, A11	3	79
3	Fc gammaRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1180-2		59
2	Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1998-2006		85
1	The Role of Pharmacoepidemiology in Industry84-106		